Снижение экспрессии гена ELOVL5 изменяет механизм ферроптоза в клетках рака молочной железы MDA-MB-231

Биотехнология. 2024. Т. 40. № 6. С. 74–83.

Razumovskaya A., Кулагин Т. А., Fatkulin A., Silkina M., Ольховик Д. М., Nikulin S.

To date, breast cancer is the most common oncological pathology among the female population both in Russia and worldwide. Previously, our laboratory team identified a significant prognostic marker for breast cancer, namely the ELOVL5 gene, the expression level of which in couple with the IGFBP6 gene allowed to predict the probability of breast cancer recurrence during the first 5 years of observation with high sensitivity (82%) and specificity (62.5%). At the same time, low expression of these genes in tumor tissue corresponded to an unfavorable prognosis. ELOVL5 is a human elongase of long-chain polyunsaturated fatty acids (LC-PUFA), the use of which is often associated with antitumor effects due to the induction of ferroptotic cell death associated with accelerated peroxidation of intracellular lipids. Since activation of ferroptosis, an alternative pathway of programmed cell death, in tumor cells is considered a promising approach to overcome drug resistance, in this work, changes in the dynamics of ferroptotic cell death, as well as the transcriptome profile of breast cancer cells with decreased ELOVL5 gene expression, were studied in detail.

Keywords: Рак молочной железы, Breast cancer, transcriptome, ELOVL5, ELOVL5, ferroptosis, ферроптоз, erastin, эрастин, транскриптомный профиль

Publication based on the results of: Изучение влияния омега-3 и омега-6 жирных кислот на опухолевые клетки (2024)